As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Hereditary ATTR amyloidosis is an aggressive, rapidly progressing, debilitating and fatal disease, and the launch of Alnylam's Onpattro (patisiran) was a milestone for patients and for the ...

Overall, Alnylam reported revenues of $232 million in this third quarter, headed by $145 million for Onpattro (patisiran), another ATTR amyloidosis therapy. At JP Morgan last month, pharmaphorum ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported results. Among these, Bristol Myers reported better-than-expected ...